newsfilter
← Latest News
GlobeNewswire·

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an acceptable approvable